Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

Court Rejects Moderna’s Challenge to Arbutus Biopharma Patents

The decision by the U.S. Court of Appeals for the Federal Circuit paves the way for a possible patent infringement complaint to be filed by Arbutus over its lipid nanoparticle technology allegedly used to help manufacture Moderna’s messenger RNA (mRNA)-based COVID-19 jab. Lipid nanoparticles are used to hold the genetic material in the vaccine and act as a delivery mechanism within the body.

Moderna previously challenged the patents before the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board, which found certain aspects of Arbutus’ patents invalid but signed off on other portions ― a decision that the federal court upheld.

 So, what happens next?

Conceivably, Arbutus could file a lawsuit against Moderna seeking royalties from vaccine sales over aspects of the patents that were deemed infringed. And it might already be eyeing a piece of the action as the vaccine maker recently projected healthy full-year 2021 product sales of between $15 to $18 billion and 2022 sales between $17 to $22 billion.

Arbutus could not be reached for comment on the matter, while Moderna told FDAnews it welcomed the federal circuit court’s decision confirming that certain patent claims were invalid but that the company disagreed “with the remainder of the decisions maintaining certain other claims.”

“We are confident that Moderna’s COVID-19 vaccine is not covered by those claims,” the spokesperson added, asserting that the company developed its own proprietary lipid nanoparticle technology.

Moderna was also recently locked in a patent dispute with the National Institutes of Health (NIH) over who deserves credit for the mRNA substance used in the company’s COVID-19 vaccine (DID, Nov. 11).

Moderna disputed that three NIH scientists helped co-invent the mRNA sequence, but later said it was willing to list the government as co-owners on its patent applications, which would enable the government to license the patent to other companies.

Neither Moderna nor the NIH returned a request for comment on whether the matter had been fully resolved.

December 6, 2021

https://www.fdanews.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies